Ziarco Pharma Ltd: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients Clinically and statistically significant reduction in signs and symptoms of moderate to severe atopic dermatitis 50% (p=0.01) improvement on the eczema severity score (EASI) at week...

Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389 50% (p=0.01) improvement on EASI score at week 8 Full data to be presented at the EAACI Congress, 12 June 2016, Vienna, Austria in a Late Breaking Oral Session DISCOVERY PARK, SANDWICH,...